Kymera Therapeutics, Inc. - COMMON STOCK (KYMR)
CUSIP: 501575104
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 81,688,465
- Total 13F shares
- 78,801,021
- Share change
- +5,986,029
- Total reported value
- $3,438,754,240
- Put/Call ratio
- 36%
- Price per share
- $43.64
- Number of holders
- 208
- Value change
- +$270,821,262
- Number of buys
- 131
- Number of sells
- 76
Quarterly Holders Quick Answers
What is CUSIP 501575104?
CUSIP 501575104 identifies KYMR - Kymera Therapeutics, Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 501575104:
Top shareholders of KYMR - Kymera Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Atlas Venture Fund X, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,504,905
|
$235,830,130 | — | 11 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
8.2%
|
6,702,450
|
$183,448,000 | — | 31 Mar 2025 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
7.9%
|
6,460,000
|
$176,810,200 | — | 31 Mar 2025 | |
| ATLAS VENTURE ASSOCIATES X, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,763,012
|
$173,161,222 | — | 11 Aug 2021 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
5.4%
|
3,803,227
|
$165,983,856 | $0 | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
7.3%
|
5,996,873
|
$164,134,413 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
7.3%
|
5,995,929
|
$164,108,577 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.4%
|
5,231,392
|
$143,183,198 | — | 31 Mar 2025 | |
| BVF INC/IL |
13F
|
Company |
6.3%
|
5,161,801
|
$141,278,493 | — | 31 Mar 2025 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
6%
|
4,896,462
|
$134,016,165 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
5.4%
|
4,409,234
|
$120,680,747 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
4%
|
3,240,313
|
$88,687,367 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.2%
|
1,760,707
|
$48,190,551 | — | 31 Mar 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.4%
|
1,168,791
|
$31,989,810 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
1,133,765
|
$31,037,845 | — | 31 Mar 2025 | |
| Redmile Group, LLC |
13F
|
Company |
1.2%
|
983,413
|
$26,916,014 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
1.1%
|
896,404
|
$24,534,578 | — | 31 Mar 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
0.94%
|
770,582
|
$22,809,227 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.97%
|
794,437
|
$21,743,741 | — | 31 Mar 2025 | |
| Merck & Co., Inc. |
13F
|
Company |
0.95%
|
772,165
|
$21,134,156 | — | 31 Mar 2025 | |
| BVF PARTNERS L P/IL |
3/4/5
|
Director, Other* |
—
mixed-class rows
|
422,145
mixed-class rows
|
$18,823,193 | +$13,955,348 | 25 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.73%
|
593,606
|
$16,246,996 | — | 31 Mar 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.73%
|
593,000
|
$16,230,410 | — | 31 Mar 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.68%
|
552,286
|
$15,116,068 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.64%
|
525,245
|
$14,375,956 | — | 31 Mar 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.64%
|
525,138
|
$14,373,027 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.62%
|
510,480
|
$13,971,838 | — | 31 Mar 2025 | |
| AJU IB Investment Co., Ltd. |
13F
|
Company |
0.56%
|
457,059
|
$12,509,705 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.52%
|
421,660
|
$11,540,834 | — | 31 Mar 2025 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.51%
|
420,045
|
$11,496,632 | — | 31 Mar 2025 | |
| Deer Management Co. LLC |
13F
|
Company |
0.51%
|
415,895
|
$11,383,046 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.48%
|
395,468
|
$10,831,809 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.47%
|
381,708
|
$10,447,348 | — | 31 Mar 2025 | |
| Capital Research Global Investors |
13F
|
Company |
0.45%
|
365,190
|
$9,995,250 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.42%
|
344,237
|
$9,421,766 | — | 31 Mar 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
0.4%
|
325,000
|
$8,895,250 | — | 31 Mar 2025 | |
| GILDER GAGNON HOWE & CO LLC |
13F
|
Company |
0.39%
|
318,381
|
$8,714,088 | — | 31 Mar 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.25%
|
202,092
|
$5,531,258 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.25%
|
201,900
|
$5,526,004 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.22%
|
183,300
|
$5,016,921 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.21%
|
172,082
|
$4,709,884 | — | 31 Mar 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.19%
|
158,338
|
$4,689,972 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.18%
|
147,620
|
$4,040,359 | — | 31 Mar 2025 | |
| Foresite Capital Management VI LLC |
13F
|
Company |
0.18%
|
146,332
|
$4,005,107 | — | 31 Mar 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.18%
|
144,224
|
$3,947,411 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.18%
|
143,238
|
$3,920,424 | — | 31 Mar 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.17%
|
142,587
|
$3,902,606 | — | 31 Mar 2025 | |
| Patient Square Capital LP |
13F
|
Company |
0.17%
|
142,201
|
$3,892,041 | — | 31 Mar 2025 | |
| Aquilo Capital Management, LLC |
13F
|
Company |
0.17%
|
138,521
|
$3,791,320 | — | 31 Mar 2025 | |
| Checkpoint Capital L.P. |
13F
|
Company |
0.17%
|
136,605
|
$3,738,879 | — | 31 Mar 2025 |
Institutional Holders of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) as of Q2 2025
As of 30 Jun 2025,
Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) was held by
208 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
78,801,021 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, Avoro Capital Advisors LLC, VANGUARD GROUP INC, BVF INC/IL, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, Atlas Venture Life Science Advisors, LLC, BlackRock, Inc., and Siren, L.L.C..
This page lists
208
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
171
Q2 2025 holders
208
Holder diff
37
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.